Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adapted TPF in locally advanced head and neck squamous cell carcinoma
NCT04356170Phase 2Completed
- Sponsor
- GORTEC
- Start
- Feb 2021
- Primary completion
- Aug 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, Cisplatin micelle injection (HA132), fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Started Feb 2021; status: completed.
02
Drugs
docetaxelCisplatin micelle injection (HA132)fluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04356170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356170.